PMA device
AvertD and AvertD Buccal Sample Collection Kit
AutoGenomics, Inc. · Opioid Use Disorder Genetic Risk Variant Detection System And Collection Kit (QZH, Class III) · First FDA decision Dec 19, 2023, newest May 20, 2026OCD, PTSD and other psychiatric conditions
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
Breakthrough-designated
Device trials
0
Naming "AvertD"
MAUDE reports
0
Brand "AvertD", since 2015
PubMed studies
1
Mentioning "AvertD"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing AvertD and AvertD Buccal Sample Collection Kit
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- AvertD and AvertD Buccal Sample Collection KitPMA supplement
P230032-S005 · Decided May 20, 2026 · 28 days after receipt · Normal 180 Day Track No User Fee
Device type: Opioid use disorder genetic risk variant detection system and collection kit (QZH) · Laboratory Medicine & Pathology
- AvertD and AvertD Buccal Sample Collection KitPMA supplement
P230032-S003 · Decided Jan 29, 2026 · 30 days after receipt · Normal 180 Day Track No User Fee
Device type: Opioid use disorder genetic risk variant detection system and collection kit (QZH) · Laboratory Medicine & Pathology
- AvertD and AvertD Buccal Sample Collection KitPMA supplement
P230032-S002 · Decided Nov 7, 2024 · 174 days after receipt · Normal 180 Day Track
Device type: Opioid use disorder genetic risk variant detection system and collection kit (QZH) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic NeoplasmsProposed local determinationProposedDL40474WPS Insurance CorporationUpdated Sep 17, 2026
- MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic NeoplasmsProposed local determinationProposedDL40407Palmetto GBAUpdated Aug 21, 2026
- MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic NeoplasmsProposed local determinationProposedDL40431CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic NeoplasmsProposed local determinationProposedDL40411Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "AvertD", any status and sponsor, newest update first.
No registered device study names "AvertD".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "AvertD", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QZH
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "AvertD"[tiab]. The summary above synthesizes these.
- Physician Liability for Genetic Risk-Based Prescription Decisions.
Gutmann Koch V · Am J Law Med · 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.